1-(4-methoxyphenyl)pyridinium has been researched along with captopril in 1 studies
| Studies (1-(4-methoxyphenyl)pyridinium) | Trials (1-(4-methoxyphenyl)pyridinium) | Recent Studies (post-2010) (1-(4-methoxyphenyl)pyridinium) | Studies (captopril) | Trials (captopril) | Recent Studies (post-2010) (captopril) |
|---|---|---|---|---|---|
| 55 | 0 | 1 | 10,320 | 1,514 | 890 |
| Protein | Taxonomy | 1-(4-methoxyphenyl)pyridinium (IC50) | captopril (IC50) |
|---|---|---|---|
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 3.6 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.084 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 0.0173 | |
| Succinyl-diaminopimelate desuccinylase | Haemophilus influenzae Rd KW20 | 3.3 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 0.1004 | |
| Beta-lactamase | Pseudomonas aeruginosa | 5 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 0.011 | |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | 3.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, MJ; Labandeira-Garcia, JL; Mendez-Alvarez, E; Muñoz, A; Rey, P; Soto-Otero, R | 1 |
1 other study(ies) available for 1-(4-methoxyphenyl)pyridinium and captopril
| Article | Year |
|---|---|
Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antiparkinson Agents; Captopril; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Immunohistochemistry; In Vitro Techniques; Lipid Peroxidation; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mitochondria; Monoamine Oxidase; Neostriatum; Nerve Degeneration; Nerve Endings; Nerve Tissue Proteins; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Pyridinium Compounds; Synaptosomes; Tyrosine 3-Monooxygenase | 2006 |